Details of Disease

General Information of Disease (ID: DISVKFN7)

• Disease Name: Candidemia
• Synonyms: Candidemias; candidemia
• Disease Class: 1F23: Candidosis
• Definition: A form of invasive candidiasis where species of candida are present in the blood.
• Disease Hierarchy:
  DIS5VDG3: Candidiasis, invasive
  DISVKFN7: Candidemia
• ICD Code:
  ICD-11: ICD-11: 1F23.3Y
  ICD-10: ICD-10: B37
  ICD-9: ICD-9: 112
  Expand ICD-11: 1F23
  Expand ICD-10: B37
  Expand ICD-9: 112
• Disease Identifiers:
  MONDO ID: MONDO_0044070
  MESH ID: D058387
  UMLS CUI: C0877445
  MedGen ID: 163760
  SNOMED CT ID: 432261003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amphotericin B	DMTAJQE	Approved	Small molecular drug	[1]
Anidulafungin	DM8QM5U	Approved	Small molecular drug	[2]
Caspofungin	DMGQIPT	Approved	Small molecular drug	[3]
Fluconazole	DMOWZ6B	Approved	Small molecular drug	[4]
Itraconazole	DMCR1MV	Approved	Small molecular drug	[5]
Micafungin	DM6Y3AN	Approved	Small molecular drug	[6]
Voriconazole	DMAOL2S	Approved	Small molecular drug	[7]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Isavuconazole	DMSV12M	Phase 3	Small molecular drug	[8]
APX-001	DMAIJC9	Phase 2	NA	[9]
HLF 1-11	DMDFG1O	Phase 1/2	Peptide	[10]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CD58	TT5KSBY	Strong	Biomarker	[11]
TIRAP	TTKU0LS	Strong	Biomarker	[12]

This Disease Is Related to 14 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CARD9	OTJ81AWD	Strong	Altered Expression	[13]
CEACAM4	OT0C7YUD	Strong	Biomarker	[14]
CLEC7A	OTRTBH27	Strong	Genetic Variation	[15]
DBF4	OTBL7JHQ	Strong	Biomarker	[16]
DOK3	OT842U3C	Strong	Altered Expression	[13]
FXYD4	OT06IH3H	Strong	Biomarker	[16]
HMX1	OT65ZGE0	Strong	Biomarker	[17]
LCE4A	OT6VQPC1	Strong	Genetic Variation	[11]
NAA35	OTHVXAXC	Strong	Genetic Variation	[18]
PER2	OTU2B1DJ	Strong	Biomarker	[19]
SUMF2	OT37I8JL	Strong	Biomarker	[20]
TAGAP	OTHJNNO2	Strong	Genetic Variation	[11]
CD101	OT4QX6BR	Definitive	Biomarker	[21]
SPTBN5	OT8MUQDU	Definitive	Genetic Variation	[22]

References

• [1] Amphotericin B FDA Label
• [2] Anidulafungin FDA Label
• [3] Caspofungin FDA Label
• [4] Fluconazole FDA Label
• [5] Itraconazole FDA Label
• [6] Micafungin FDA Label
• [7] Voriconazole FDA Label
• [8] ClinicalTrials.gov (NCT00634049) Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT03604705) An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT00509834) A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia (SLIC). U.S. National Institutes of Health.
• [11] Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia.Nat Commun. 2014 Sep 8;5:4675. doi: 10.1038/ncomms5675.
• [12] Toll-like receptor 1 polymorphisms increase susceptibility to candidemia.J Infect Dis. 2012 Mar 15;205(6):934-43. doi: 10.1093/infdis/jir867. Epub 2012 Feb 1.
• [13] Dok3-protein phosphatase 1 interaction attenuates Card9 signaling and neutrophil-dependent antifungal immunity.J Clin Invest. 2019 Jun 10;129(7):2717-2729. doi: 10.1172/JCI126341. eCollection 2019 Jun 10.
• [14] The emergence of non-albicans candidemia and evaluation of HiChrome Candida differential agar and VITEK2 YST platform for differentiation of Candida bloodstream isolates in teaching hospital Kandy, Sri Lanka.BMC Microbiol. 2019 Jun 21;19(1):136. doi: 10.1186/s12866-019-1518-3.
• [15] Host-microbe interactions in stem cell transplantation: recognizing Candida in infection and inflammation.Virulence. 2010 May-Jun;1(3):180-4. doi: 10.4161/viru.1.3.11208.
• [16] Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy.BMC Infect Dis. 2015 Aug 18;15:340. doi: 10.1186/s12879-015-1086-6.
• [17] MiR-204/miR-211 downregulation contributes to candidemia-induced kidney injuries via derepression of Hmx1 expression.Life Sci. 2014 May 2;102(2):139-44. doi: 10.1016/j.lfs.2014.03.010. Epub 2014 Mar 15.
• [18] Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi.Nat Med. 2016 Aug;22(8):952-60. doi: 10.1038/nm.4139. Epub 2016 Jul 4.
• [19] Secular trends of candidemia at a Brazilian tertiary care teaching hospital.Braz J Infect Dis. 2018 Jul-Aug;22(4):273-277. doi: 10.1016/j.bjid.2018.07.008. Epub 2018 Aug 16.
• [20] Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature.Infection. 2015 Dec;43(6):777-81. doi: 10.1007/s15010-015-0798-2. Epub 2015 May 30.
• [21] Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.Antimicrob Agents Chemother. 2018 May 25;62(6):e02603-17. doi: 10.1128/AAC.02603-17. Print 2018 Jun.
• [22] A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans.J Infect Dis. 2019 Jul 31;220(5):862-872. doi: 10.1093/infdis/jiz206.